# National Cancer Institute (NCI): Phase 2 study started recruiting, 162 planned (Core Binding Factor Acute Myeloid Leukemia)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Sponsor type | NIH |
| Study | Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) |
| NCT ID | NCT06917911 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Core Binding Factor Acute Myeloid Leukemia |
| Intervention types | procedure, drug |
| Target enrollment | 162 |
| Site countries | United States, Puerto Rico |
| Posted | 2025-04-09 |
| Planned start | 2026-09-28 |
| Event | Started recruiting |
| Event date | 2026-09-28 |
| Last update posted | 2026-11-04 |

## Why this score
- Posted in the last two weeks.
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.
- 162 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06917911). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.